October 11, 2012 ·
Leave a comment
Thought Leader Select is pleased to announce that Allison Murphy, an executive with nearly two decades of experience working in healthcare and biopharmaceuticals, has joined the company’s team of consultants dedicated to optimizing industry collaborations with medical experts.
Murphy comes to Thought Leader Select with a track record of success in clinical work at leading medical centers of excellence, as well as sales and medical science liaison roles at Eli Lilly and Company. A 1993 graduate of Villanova University with a degree in nursing, Murphy entered clinical practice in a role leading pediatric oncology nurse teams at New York University Lagone Medical Center, followed by a stint working as a nurse coordinator in pediatric endocrinology at Columbia Presbyterian Medical Center, also in New York.
During her time at Columbia Presbyterian, Ms. Murphy managed a practice that grew from 300 to over 2000 weekly patient visits and served as study coordinator for multiple National Institutes of Health-sponsored protocols and several phase IV clinical trial collaborations with the pharmaceutical industry.
In 2001, Murphy began an 11-year run at Eli Lilly, first working as a sales specialist on behalf of the company’s portfolio of products aimed at growth disorders to help both pediatric and adult endocrinologists. Murphy ... read more »
TAGS: 
Allison Murphy biopharmaceuticals Columbia Presbyterian Medical Center devices diabetes thought leaders diagnostics early-stage drug development Eli Lilly endocrinology KOL engagement KOL identification KOL profiling medical science liaison NYU Lagone Medical Center Oncology oncology KOLs pediatric endocrinology pediatric oncology product planning product strategy Thought Leader Select Thought Leader Select consulting team
March 11, 2011 ·
Leave a comment
Service Spotlight with Brian Castle
People ask me almost every day what makes Thought Leader Select different from the three dozen or so competitors we have in the thought leader services micro-niche within healthcare and biopharmaceuticals. Obviously, that’s a dangerous question to ask a marketing person! After all, I spend days on end composing multiple arguments to make the very case that we are uniquely positioned to help client companies in ways that many of our competitors haven’t even conceived.
What makes my job easy is that we are different. Very different, in fact. I know that lots of companies claim that their people are the difference, but that concept is especially true at Thought Leader Select. In addition to having a front-end consulting team with over 50 years of healthcare and biopharmaceutical industry experience, we have a back-end research team with over 50 years of clinical and research work in the field of medicine. Led by Lisa Smith, Clarissa Noureddine, Rhonda Napier, Lynda Scott, and Cammie Brannan, our research team delivers research assessments on the skills and experiences of thought leaders around the world.
Our team complements each assessment with technology tools (such our proprietary database, Thought Leader Index) and advisory capabilities that add an element to our work that other firms ... read more »
TAGS: biopharmaceuticals Cammie Brannan Clarissa Noureddine clinical practice consulting healthcare investigative journalism key opinion leaders KOL engagement KOL identification KOL mapping KOL profiling KOL services Lisa Smith Lynda Scott medical researchers research Rhonda Napier scenario planning subject matter experts Thought Leader Index Thought Leader Select thought leader services thought leaders
September 15, 2010 ·
3 comments
Industry Insights from Paul Meade, M. Sc, MPH
When the Human Genome Project was finally completed with the mapping of the genetic sequences of our DNA, there were many predictions about how the face of medicine would change forever. We would finally figure out how to cure diseases linked to genetic aberrations, find ways to enhance our interaction with the environment, and develop medicines that are tailored to fit our unique genome. But a decade later, we are all aware of just how painfully slow progress has been to date. However, one area that is advancing steadily is the use of companion diagnostics.
Everyone was quick to point to Herceptin and the prototype example of a diagnostic test that was required to be use prior to prescribing this chemotherapeutic agent for women with breast cancer that over-expressed the HER2/neu gene. But now there are more examples of such companion diagnostics, and the list continues to grow.
What does all this mean for the future of medicine, and the interaction among the diagnostic and biopharmaceutical companies? When we can go to a physician’s office, be correctly diagnosed, and then given a medicine to take knowing in advance that we will have a high probability of responding, without suffering from annoying side effects, then we will have personalized medicine.
Does that mean that people will have ... read more »
TAGS: biopharmaceuticals breast cancer chemotherapeutic agents companion diagnostics diagnosis diagnostic tests DNA genetic sequences genetic type genetics genome genotype Herceptin Human Genome Project medicine personalized medicine physicians prescription drugs
